CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Factors to Note CRISPR Therapeutics' top line comprises grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals VRTX. Revenues in the to-be-reported quarter are likely to have been driven by collaboration revenues from Vertex. The Zacks Consensus Estimate for total revenues stands at $8.31 million. Casgevy is the first marketed product in CRISPR Therapeutics' portfolio. Vertex leads the global development and commercialization of Casgevy under the terms of a 60/40 profit-sharing agreement with CRISPR Therapeutics. In December 2023, the FDA approved CRSP and VRTX's gene therapy, Casgevy, for treating sickle cell disease (SCD) in patients aged 12 years and older. Consequently, the FDA has expanded Casgevy's label to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older in early 2024. The European Commission approved Casgevy for the treatment of patients aged 12 years and older with severe SCD and TD
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- How Gene Editing Therapies Could Go Beyond Rare Diseases [Forbes]Forbes
- Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higher [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $102.00 to $95.00. They now have an "outperform" rating on the stock.MarketBeat
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 4/17/24 - Form 4
- CRSP's page on the SEC website